A.A. Klimenko, A.A. Kondrashov 

Pirogov Russian National Research Medical University, Moscow 

Osteoarthritis (OA) is the most common joint disease and cause of limited physical activity and decreased life quality in adult patients. There is a tendency of the "age rejuvenation" of the OA onset. The disease can affect almost any joint and is characterized by pathological changes in cartilage, subchondral bone, synovial membrane, ligaments, muscles and periarticular adipose tissue, which causes the development of the main set of disease symptoms. Patients with OA have more comorbidities and are sedentary versus those without OA. A decrease in physical activity leads to an increase in mortality. The basis of OA treatment includes physical exercises, weight loss in combination with the use of basic OA therapy, the choice of which is based on the phenotype of the disease and comorbid conditions. The review is devoted to the basic OA therapy, in particular with symptomatic slow-acting drugs in osteoarthritis (SYSADOA). Diacerein is one of the drugs of the SY SADOA group that has not only a symptom- and structurally-modifying effect but also a good safety profile in patients with cardiovascular diseases, type 2 diabetes mellitus and metabolic syndrome. It is confirmed by a large number of clinical research results.

Keywords: osteoarthritis, comorbidity, symptomatic slow-acting drugs, nonsteroidal anti-inflammatory drugs, diacerein.

For citation: Klimenko A.A., Kondrashov A.A. Osteoarthritis: basic therapy peculiarities. RMJ. 2022;6:46–50.